
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9291413/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncology, The, 2020, 21, e18-e28.	10.7	588
2	An Individual Patient Data Metaanalysis of Outcomes and Prognostic Factors After Treatment of Oligometastatic Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2014, 15, 346-355.	2.6	377
3	Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiotherapy and Oncology, 2020, 148, 157-166.	0.6	352
4	ESTRO-ACROP guideline "target delineation of glioblastomasâ€: Radiotherapy and Oncology, 2016, 118, 35-42.	0.6	286
5	SIOP CNS GCT 96: final report of outcome of a prospective, multinational nonrandomized trial for children and adults with intracranial germinoma, comparing craniospinal irradiation alone with chemotherapy followed by focal primary site irradiation for patients with localized disease. Neuro-Oncology, 2013, 15, 788-796.	1.2	277
6	Stereotactic body radiation therapy for early stage non-small cell lung cancer: Results of a prospective trial. Lung Cancer, 2010, 68, 72-77.	2.0	268
7	Modern Radiation Therapy for Nodal Non-Hodgkin Lymphoma—Target Definition and Dose Guidelines From the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2014, 89, 49-58.	0.8	259
8	Epidemiology of glial and non-glial brain tumours in Europe. European Journal of Cancer, 2012, 48, 1532-1542.	2.8	248
9	First-Line Treatment for Primary Testicular Diffuse Large B-Cell Lymphoma With Rituximab-CHOP, CNS Prophylaxis, and Contralateral Testis Irradiation: Final Results of an International Phase II Trial. Journal of Clinical Oncology, 2011, 29, 2766-2772.	1.6	190
10	Review and Uses of Stereotactic Body Radiation Therapy for Oligometastases. Oncologist, 2012, 17, 1100-1107.	3.7	185
11	Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review. Cancer Treatment Reviews, 2017, 53, 25-37.	7.7	169
12	Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement. Radiotherapy and Oncology, 2020, 146, 223-229.	0.6	168
13	Clinical use of EBT model Gafchromicâ,,¢ film in radiotherapy. Medical Physics, 2006, 33, 4314-4319.	3.0	153
14	Outcome of patients with intracranial non-germinomatous germ cell tumors—lessons from the SIOP-CNS-GCT-96 trial. Neuro-Oncology, 2017, 19, 1661-1672.	1.2	150
15	ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer. Radiotherapy and Oncology, 2018, 127, 1-5.	0.6	141
16	Stereotactic body radiation therapy for lung metastases. Lung Cancer, 2012, 75, 77-81.	2.0	133
17	Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. Blood, 2018, 131, 1456-1463.	1.4	130
18	Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2018, 101, 794-808.	0.8	128

#	Article	IF	CITATIONS
19	Pediatric medulloblastoma: Toxicity of current treatment and potential role of protontherapy. Cancer Treatment Reviews, 2009, 35, 79-96.	7.7	123
20	Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: A phase-II parallel non-randomized and observation study (EORTC 22042-26042). Radiotherapy and Oncology, 2018, 128, 260-265.	0.6	123
21	Treatment of brain metastases: Review of phase III randomized controlled trials. Radiotherapy and Oncology, 2012, 102, 168-179.	0.6	117
22	Swallowing dysfunction in head and neck cancer patients treated by radiotherapy: Review and recommendations of the supportive task group of the Italian Association of Radiation Oncology. Cancer Treatment Reviews, 2012, 38, 1033-1049.	7.7	106
23	Eighth Edition of the UICC Classification of Malignant Tumours: an overview of the changes in the pathological TNM classification criteria—What has changed and why?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 519-531.	2.8	106
24	Different IMRT solutions vs. 3D-Conformal Radiotherapy in early stage Hodgkin's lymphoma: dosimetric comparison and clinical considerations. Radiation Oncology, 2012, 7, 186.	2.7	96
25	Hyperfractionated radiotherapy and chemotherapy for childhood ependymoma: final results of the first prospective AIEOP (Associazione Italiana di Ematologia-Oncologia Pediatrica) study. International Journal of Radiation Oncology Biology Physics, 2004, 58, 1336-1345.	0.8	93
26	Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. Blood, 2009, 113, 3375-3382.	1.4	92
27	Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG. Blood, 2019, 133, 237-245.	1.4	85
28	Role of Positron Emission Tomography-Computed Tomography in the Management of Anal Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 84, 66-72.	0.8	83
29	ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic. Blood, 2020, 135, 1829-1832.	1.4	78
30	Long-term local control achieved after hypofractionated stereotactic body radiotherapy for adrenal gland metastases: A retrospective analysis of 34 patients. Acta Oncológica, 2012, 51, 618-623.	1.8	76
31	A rapid flow cytometry test based on histone H2AX phosphorylation for the sensitive and specific diagnosis of ataxia telangiectasia. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2008, 73A, 508-516.	1.5	73
32	Patterns of Care and Survival in a Retrospective Analysis of 1059 Patients With Glioblastoma Multiforme Treated Between 2002 and 2007. Neurosurgery, 2010, 67, 446-458.	1.1	73
33	Stereotactic Ablative Radiotherapy for stage I histologically proven non-small cell lung cancer: An Italian multicenter observational study. Lung Cancer, 2014, 84, 248-253.	2.0	73
34	Comparison of Positron Emission Tomography Scanning and Sentinel Node Biopsy in the Detection of Inguinal Node Metastases in Patients With Anal Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 77, 73-78.	0.8	67
35	Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines. International Journal of Radiation Oncology Biology Physics, 2020, 107, 909-933.	0.8	67
36	Evidence-based Review on the Use of Proton Therapy in Lymphoma From the Particle Therapy Cooperative Group (PTCOG) Lymphoma Subcommittee. International Journal of Radiation Oncology Biology Physics, 2017, 99, 825-842.	0.8	66

#	Article	IF	CITATIONS
37	Thyroid dysfunction as a late effect in childhood medulloblastoma: a comparison of hyperfractionated versus conventionally fractionated craniospinal radiotherapy. International Journal of Radiation Oncology Biology Physics, 2001, 50, 1287-1294.	0.8	65
38	Running a Radiation Oncology Department at the Time of Coronavirus: An Italian Experience. Advances in Radiation Oncology, 2020, 5, 527-530.	1.2	65
39	Stereotactic Ablative Radiation Therapy as First Local Therapy for Lung Oligometastases From Colorectal Cancer: A Single-Institution Cohort Study. International Journal of Radiation Oncology Biology Physics, 2015, 91, 524-529.	0.8	64
40	Stereotactic body radiotherapy for early stage lung cancer: History and updated role. Lung Cancer, 2015, 90, 388-396.	2.0	62
41	Rare thoracic cancers, including peritoneum mesothelioma. European Journal of Cancer, 2012, 48, 949-960.	2.8	61
42	Dosimetric predictors of radiation-induced lung injury in stereotactic body radiation therapy. Acta Oncológica, 2009, 48, 571-577.	1.8	60
43	Predictive parameters of symptomatic radiation pneumonitis following stereotactic or hypofractionated radiotherapy delivered using volumetric modulated arcs. Radiotherapy and Oncology, 2013, 109, 95-99.	0.6	55
44	Optimized Volumetric Modulated Arc Therapy Versus 3D-CRT for Early Stage Mediastinal Hodgkin Lymphoma Without Axillary Involvement: A Comparison of Second Cancers and Heart Disease Risk. International Journal of Radiation Oncology Biology Physics, 2015, 92, 161-168.	0.8	55
45	Effect of COVID-19 pandemic on practice in European radiation oncology centers. Radiotherapy and Oncology, 2020, 150, 40-42.	0.6	53
46	Second Italian Consensus Conference on Malignant Pleural Mesothelioma: State of the art and recommendations. Cancer Treatment Reviews, 2013, 39, 328-339.	7.7	51
47	Evaluation of Definitive Stereotactic Body Radiotherapy and Outcomes in Adults With Extracranial Oligometastasis. JAMA Network Open, 2020, 3, e2026312.	5.9	51
48	Outcomes of Single Fraction Stereotactic Ablative Radiotherapy for Lung Metastases. Technology in Cancer Research and Treatment, 2014, 13, 37-45.	1.9	49
49	Stereotactic Ablative Radiotherapy for Pulmonary Oligometastases and Oligometastatic Lung Cancer. Journal of Thoracic Oncology, 2014, 9, 1426-1433.	1.1	49
50	Involved-Site Image-Guided Intensity Modulated Versus 3D Conformal Radiation Therapy in Early Stage Supradiaphragmatic Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics, 2014, 89, 370-375.	0.8	46
51	The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1100-1118.	0.8	46
52	Radiotherapy and immune checkpoints inhibitors for advanced melanoma. Radiotherapy and Oncology, 2016, 120, 1-12.	0.6	44
53	Separation surgery for metastatic epidural spinal cord compression: A qualitative review. Journal of Bone Oncology, 2020, 25, 100320.	2.4	43
54	COVID-19 outbreak and cancer radiotherapy disruption in Italy: Survey endorsed by the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Radiotherapy and Oncology, 2020, 149, 89-93.	0.6	43

#	Article	IF	CITATIONS
55	Intensity-modulated and hypofractionated simultaneous integrated boost adjuvant breast radiation employing statics ports of tomotherapy (TomoDirect): a prospective phase II trial. Journal of Cancer Research and Clinical Oncology, 2014, 140, 167-177.	2.5	42
56	Intensity-Modulated Radiation Therapy with Simultaneous Integrated Boost Combined with Concurrent Chemotherapy for the Treatment of Anal Cancer Patients: 4-Year Results of a Consecutive Case Series. Cancer Investigation, 2015, 33, 259-266.	1.3	42
57	Accessibility as a major determinant of radiotherapy underutilization: A population based study. Health Policy, 2007, 80, 483-491.	3.0	41
58	Interim positron emission tomography and clinical outcome in patients with early stage Hodgkin lymphoma treated with combined modality therapy. Leukemia and Lymphoma, 2013, 54, 1183-1187.	1.3	41
59	Intensity-modulated adjuvant whole breast radiation delivered with static angle tomotherapy (TomoDirect): a prospective case series. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1927-1936.	2.5	41
60	Results of Neoadjuvant Short-Course Radiation Therapy Followed by Transanal Endoscopic Microsurgery for T1-T2 NO Extraperitoneal Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 92, 299-306.	0.8	41
61	Stereotactic radiotherapy for early stage non-small cell lung cancer. Radiation Oncology Journal, 2015, 33, 57.	1.5	41
62	Practice Recommendations for Lung Cancer Radiotherapy During the COVID-19 Pandemic: An ESTRO-ASTRO Consensus Statement. International Journal of Radiation Oncology Biology Physics, 2020, 107, 631-640.	0.8	40
63	Volumetric modulated arc therapy (VMAT) in the combined modality treatment of anal cancer patients. British Journal of Radiology, 2016, 89, 20150832.	2.2	38
64	Pulmonary function and quality of life after VMAT-based stereotactic ablative radiotherapy for early stage inoperable NSCLC: a prospective study. Lung Cancer, 2015, 89, 350-356.	2.0	37
65	Residual γH2AX foci after ex vivo irradiation of patient samples with known tumour-type specific differences in radio-responsiveness. Radiotherapy and Oncology, 2015, 116, 480-485.	0.6	37
66	Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1546-1562.	6.4	37
67	Prospective assessment of oral mucositis and its impact on quality of life and patient-reported outcomes during radiotherapy for head and neck cancer. Medical Oncology, 2017, 34, 81.	2.5	37
68	Radiation Therapy in Primary Mediastinal B-Cell Lymphoma With Positron Emission Tomography Positivity After Rituximab Chemotherapy. International Journal of Radiation Oncology Biology Physics, 2013, 87, 311-316.	0.8	35
69	Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study. International Journal of Radiation Oncology Biology Physics, 2016, 94, 783-791.	0.8	35
70	Tumor Bed Boost Integration during Whole Breast Radiotherapy: A Review of the Current Evidence. Breast Care, 2015, 10, 44-49.	1.4	34
71	Treatment With Oral Etoposide for Childhood Recurrent Ependymomas. Journal of Pediatric Hematology/Oncology, 2005, 27, 486-490.	0.6	33
72	TomoDirect: An efficient means to deliver radiation at static angles with tomotherapy. Tumori, 2011, 97, 498-502.	1.1	33

#	Article	IF	CITATIONS
73	Does TomoDirect 3DCRT represent a suitable option for post-operative whole breast irradiation? A hypothesis-generating pilot study. Radiation Oncology, 2012, 7, 211.	2.7	33
74	Hypericum perforatum and neem oil for the management of acute skin toxicity in head and neck cancer patients undergoing radiation or chemo-radiation: a single-arm prospective observational study. Radiation Oncology, 2014, 9, 297.	2.7	33
75	Once-Weekly Hypofractionated Whole-Breast Radiotherapy After Breast-Conserving Surgery in Older Patients: A Potential Alternative Treatment Schedule to Daily 3-Week Hypofractionation. Clinical Breast Cancer, 2015, 15, 270-276.	2.4	33
76	Imageâ€guided IMRT with simultaneous integrated boost as per RTOG 0529 for the treatment of anal cancer. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 217-223.	1.1	33
77	Palliative radiotherapy indications during the COVID-19 pandemic and in future complex logistic settings: the NORMALITY model. Radiologia Medica, 2021, 126, 1619-1656.	7.7	33
78	Radiation therapy for older patients with brain tumors. Radiation Oncology, 2017, 12, 101.	2.7	32
79	Inclusion of heart substructures in the optimization process of volumetric modulated arc therapy techniques may reduce the risk of heart disease in Hodgkin's lymphoma patients. Radiotherapy and Oncology, 2019, 138, 52-58.	0.6	32
80	Late Toxicity in Children Undergoing Hematopoietic Stem Cell Transplantation with TBI-containing Conditioning Regimens for Hematological Malignancies. Strahlentherapie Und Onkologie, 2009, 185, 17-20.	2.0	31
81	Five-year results of a prospective case series of accelerated hypofractionated whole breast radiation with concomitant boost to the surgical bed after conserving surgery for early breast cancer. Medical Oncology, 2013, 30, 518.	2.5	31
82	Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma. International Journal of Radiation Oncology Biology Physics, 2017, 97, 42-49.	0.8	31
83	Clinical applications of stereotactic radiation therapy for oligometastatic cancer patients: a disease-oriented approach. Journal of Radiation Research, 2016, 57, i58-i68.	1.6	30
84	Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. Blood, 2020, 135, 2365-2374.	1.4	30
85	Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism. Nature Medicine, 2022, 28, 752-765.	30.7	30
86	Daily Sodium Butyrate Enema for the Prevention of Radiation Proctitis in Prostate Cancer Patients Undergoing Radical Radiation Therapy: Results of a Multicenter Randomized Placebo-Controlled Dose-Finding Phase 2 Study. International Journal of Radiation Oncology Biology Physics, 2014, 89, 518-524.	0.8	29
87	Intensity Modulated Radiation Therapy and Second Cancer Risk in Adults. International Journal of Radiation Oncology Biology Physics, 2018, 100, 17-20.	0.8	29
88	TomoDirect: an efficient means to deliver radiation at static angles with tomotherapy. Tumori, 2011, 97, 498-502.	1.1	29
89	Efficacy and Safety of Tadalafil 20mg on Demand vs. Tadalafil 5mg Once-a-Day in the Treatment of Post-Radiotherapy Erectile Dysfunction in Prostate Cancer Men: A Randomized Phase II Trial. Journal of Sexual Medicine, 2010, 7, 2851-2859.	0.6	28
90	Interobserver variability of clinical target volume delineation in supra-diaphragmatic Hodgkin's disease. Strahlentherapie Und Onkologie, 2011, 187, 357-366.	2.0	28

#	Article	IF	CITATIONS
91	Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2015, 92, 1077-1083.	0.8	28
92	Toxicity and cosmetic outcome after hypofractionated whole breast irradiation and boost-IOERT in early stage breast cancer (HIOB): First results of a prospective multicenter trial (NCT01343459). Radiotherapy and Oncology, 2020, 146, 136-142.	0.6	28
93	Immunotherapy in association with stereotactic radiotherapy for non-small cell lung cancer brain metastases: results from a multicentric retrospective study on behalf of AIRO. Neuro-Oncology, 2021, 23, 1750-1764.	1.2	28
94	Dose to specific subregions of pelvic bone marrow defined with FDG-PET as a predictor of hematologic nadirs during concomitant chemoradiation in anal cancer patients. Medical Oncology, 2016, 33, 72.	2.5	27
95	Short fractionation radiotherapy for early prostate cancer in the time of COVID-19: long-term excellent outcomes from a multicenter Italian trial suggest a larger adoption in clinical practice. Radiologia Medica, 2021, 126, 142-146.	7.7	27
96	Radiotherapy and temozolomide in anaplastic astrocytoma: a retrospective multicenter study by the Central Nervous System Study Group of AIRO (Italian Association of Radiation Oncology). Neuro-Oncology, 2012, 14, 798-807.	1.2	26
97	A multi-national report on stereotactic body radiotherapy for oligometastases: Patient selection and follow-up*. Acta Oncológica, 2016, 55, 633-637.	1.8	26
98	Current state of interventional radiotherapy (brachytherapy) education in Italy: results of the INTERACTS survey. Journal of Contemporary Brachytherapy, 2019, 11, 48-53.	0.9	26
99	Modern Radiation Therapy for Extranodal Nasal-Type NK/T-cell Lymphoma: Risk-Adapted Therapy, Target Volume, and Dose Guidelines from the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1064-1081.	0.8	26
100	Multicenter Experience Using Total Lymphoid Irradiation and Antithymocyte Globulin as Conditioning for Allografting in Hematological Malignancies. Biology of Blood and Marrow Transplantation, 2012, 18, 1600-1607.	2.0	25
101	Comparison of Gafchromic EBT2 and EBT3 for patient-specific quality assurance: Cranial stereotactic radiosurgery using volumetric modulated arc therapy with multiple noncoplanar arcs. Medical Physics, 2013, 40, 082105.	3.0	25
102	Plan optimization for mediastinal radiotherapy: Estimation of coronary arteries motion with ECG-gated cardiac imaging and creation of compensatory expansion margins. Radiotherapy and Oncology, 2018, 127, 481-486.	0.6	25
103	Locally-advanced non-small cell lung cancer: shall immunotherapy be a new chance?. Journal of Thoracic Disease, 2018, 10, S1461-S1467.	1.4	25
104	Modern Radiation Therapy for the Management of Brain Metastases From Non-Small Cell Lung Cancer: Current Approaches and Future Directions. Frontiers in Oncology, 2021, 11, 772789.	2.8	25
105	Is Clinical Radiosensitivity a Complex Genetically Controlled Event?. Tumori, 2006, 92, 87-91.	1.1	24
106	Micropapillary ductal carcinoma in situ of the breast: an inter-institutional study. Modern Pathology, 2010, 23, 260-269.	5.5	24
107	De-escalation of breast radiotherapy after conserving surgery in low-risk early breast cancer patients. Medical Oncology, 2018, 35, 62.	2.5	24
108	Volumetric modulated arc therapy (VMAT) to deliver nodal irradiation in breast cancer patients. Medical Oncology, 2018, 35, 1.	2.5	24

UMBERTO RICARDI

#	Article	IF	CITATIONS
109	Radiation Oncology. Optimal Health for All, Together. ESTRO vision, 2030. Radiotherapy and Oncology, 2019, 136, 86-97.	0.6	24
110	Oncological outcomes of salvage radical prostatectomy for recurrent prostate cancer in the contemporary era: A multicenter retrospective study. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 296.e21-296.e29.	1.6	24
111	Patterns of practice and survival in a retrospective analysis of 1722 adult astrocytoma patients treated between 1985 and 2001 in 12 Italian radiation oncology centers. International Journal of Radiation Oncology Biology Physics, 2006, 65, 788-799.	0.8	23
112	Squamous cell carcinoma of the prostate: long-term survival after combined chemo-radiation. Radiation Oncology, 2007, 2, 15.	2.7	23
113	The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer. Radiation Oncology, 2018, 13, 83.	2.7	23
114	<p>Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response) Tj ETQq0 0 0</p>	rg B.T 9/Ove	rlo 21 10 Tf 50
115	ESTRO ACROP guidelines for target volume definition in the thoracic radiation treatment of small cell lung cancer. Radiotherapy and Oncology, 2020, 152, 89-95.	0.6	23
116	Is the combination of Cetuximab with chemo-radiotherapy regimens worthwhile in the treatment of locally advanced head and neck cancer? A review of current evidence. Critical Reviews in Oncology/Hematology, 2013, 85, 112-120.	4.4	21
117	Hypofractionation and concomitant boost to deliver adjuvant whole-breast radiation in ductal carcinoma in situ (DCIS): a subgroup analysis of a prospective case series. Medical Oncology, 2014, 31, 838.	2.5	21
118	Is stereotactic ablative radiotherapy an alternative to surgery in operable stage I non-small cell lung cancer?. Reports of Practical Oncology and Radiotherapy, 2014, 19, 275-279.	0.6	21
119	Radiation Therapy for Primary Cutaneous Anaplastic Large Cell Lymphoma: An International Lymphoma Radiation Oncology Group Multi-institutional Experience. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1454-1459.	0.8	21
120	An analysis of a large multi-institutional database reveals important associations between treatment parameters and clinical outcomes for stereotactic body radiotherapy (SBRT) of oligometastatic colorectal cancer. Radiotherapy and Oncology, 2022, 167, 187-194.	0.6	21
121	Prognostic Role of Pre–Radiation Therapy 18F-Fluorodeoxyglucose Positron Emission Tomography for Primary Mediastinal B-Cell Lymphomas Treated with R-CHOP or R-CHOP-Like Chemotherapy Plus Radiation. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1239-1243.	0.8	20
122	Incorporating 18FDG-PET-defined pelvic active bone marrow in the automatic treatment planning process of anal cancer patients undergoing chemo-radiation. BMC Cancer, 2017, 17, 710.	2.6	20
123	Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO). Radiologia Medica, 2018, 123, 48-62.	7.7	20
124	Variability of clinical target volume delineation for rectal cancer patients planned for neoadjuvant radiotherapy with the aid of the platform Anatom-e. Clinical and Translational Radiation Oncology, 2018, 11, 33-39.	1.7	20
125	The role of radiotherapy in epithelial ovarian cancer: a literature overview. Medical Oncology, 2019, 36, 64.	2.5	20
126	Fondazione Italiana Linfomi (FIL) expert consensus on the use of intensity-modulated and image-guided radiotherapy for Hodgkin's lymphoma involving the mediastinum. Radiation Oncology, 2020, 15, 62.	2.7	20

#	Article	IF	CITATIONS
127	Changes in breast cancer risk associated with different volumes, doses, and techniques in female Hodgkin lymphoma patients treated with supra-diaphragmatic radiation therapy. Practical Radiation Oncology, 2013, 3, 216-222.	2.1	19
128	Late Sensorial Alterations in Different Radiotherapy Techniques for Nasopharyngeal Cancer. Chemical Senses, 2015, 40, 285-292.	2.0	19
129	Hematologic toxicity in anal cancer patients during combined chemo-radiation: a radiation oncologist perspective. Expert Review of Anticancer Therapy, 2017, 17, 335-345.	2.4	19
130	Potential Benefit of Involved-Field Radiotherapy for Patients With Relapsed-Refractory Hodgkin's Lymphoma With Incomplete Response Before Autologous Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 14-22.	0.4	19
131	Comparing simultaneous integrated boost vs sequential boost in anal cancer patients: results of a retrospective observational study. Radiation Oncology, 2018, 13, 172.	2.7	19
132	Role of radiotherapy in improving activity of immune-modulating drugs in advanced renal cancer: Biological rationale and clinical evidences. Cancer Treatment Reviews, 2018, 69, 215-223.	7.7	19
133	Prospective assessment of taste impairment and nausea during radiotherapy for head and neck cancer. Medical Oncology, 2019, 36, 44.	2.5	19
134	<p>Ocular Complications After Radiation Therapy: An Observational Study</p> . Clinical Ophthalmology, 2020, Volume 14, 3153-3166.	1.8	19
135	Postoperative Radiotherapy for Patients With Completely Resected Pathologic N2 Non–Small-Cell Lung Cancer: A Retrospective Analysis. Clinical Lung Cancer, 2013, 14, 194-199.	2.6	18
136	Radiosurgery/stereotactic radiotherapy in combination with immunotherapy and targeted agents for melanoma brain metastases. Expert Review of Anticancer Therapy, 2017, 17, 347-356.	2.4	18
137	Ex vivo γH2AX radiation sensitivity assay in prostate cancer: Inter-patient and intra-patient heterogeneity. Radiotherapy and Oncology, 2017, 124, 386-394.	0.6	18
138	Bone Marrow-Sparing IMRT in Anal Cancer Patients Undergoing Concurrent Chemo-Radiation: Results of the First Phase of a Prospective Phase II Trial. Cancers, 2020, 12, 3306.	3.7	18
139	Sequential chemo-hypofractionated RT versus concurrent standard CRT for locally advanced NSCLC: GRADE recommendation by the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Radiologia Medica, 2021, 126, 1117-1128.	7.7	18
140	Locally Advanced (T3-T4 or N+) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy. Anticancer Research, 2016, 36, 2027-32.	1.1	18
141	Two-tier analysis of histone H2AX phosphorylation allows the identification of Ataxia Telangiectasia heterozygotes. Radiotherapy and Oncology, 2009, 92, 133-137.	0.6	17
142	Early Stage Lung Cancer: Progress in the Last 40 Years. Journal of Thoracic Oncology, 2014, 9, 1434-1442.	1.1	17
143	<p>Proton Therapy For Lymphomas: Current State Of The Art</p> . OncoTargets and Therapy, 2019, Volume 12, 8033-8046.	2.0	17
144	Mixed-beam approach in locally advanced nasopharyngeal carcinoma: IMRT followed by proton therapy boost versus IMRT-only. Evaluation of toxicity and efficacy. Acta Oncológica, 2020, 59, 541-548.	1.8	17

#	Article	IF	CITATIONS
145	The Impact of Pelvic Nodal Radiotherapy on Hematologic Toxicity: A Systematic Review with Focus on Leukopenia, Lymphopenia and Future Perspectives in Prostate Cancer Treatment. Critical Reviews in Oncology/Hematology, 2021, 168, 103497.	4.4	17
146	Novel radiotherapy techniques for involved-field and involved-node treatment of mediastinal Hodgkin lymphoma. Strahlentherapie Und Onkologie, 2014, 190, 864-871.	2.0	16
147	Salvage Treatment and Survival for Relapsed Follicular Lymphoma Following Primary Radiation Therapy: A Collaborative Study on Behalf of ILROG. International Journal of Radiation Oncology Biology Physics, 2019, 104, 522-529.	0.8	16
148	Radiation-Induced Rhinitis: Cytological and Olfactory Changes. American Journal of Rhinology and Allergy, 2019, 33, 153-161.	2.0	16
149	MET mutations are associated with aggressive and radioresistant brain metastatic non-small-cell lung cancer: Table 1 Neuro-Oncology, 2016, 18, 598-599.	1.2	15
150	Radiotherapy in patients with HIV: current issues and review of the literature. Lancet Oncology, The, 2017, 18, e379-e393.	10.7	15
151	Quality of Life After Prostate Cancer Diagnosis: Data from the Pros-IT CNR. European Urology Focus, 2017, 3, 321-324.	3.1	15
152	Early-stage Node-negative (T1-T2N0) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy. Anticancer Research, 2016, 36, 1943-8.	1.1	15
153	New concepts and insights into the role of radiation therapy in extracranial metastatic disease. Expert Review of Anticancer Therapy, 2013, 13, 1145-1155.	2.4	14
154	YKL-40/c-Met Expression in Rectal Cancer Biopsies Predicts Tumor Regression following Neoadjuvant Chemoradiotherapy: A Multi-Institutional Study. PLoS ONE, 2015, 10, e0123759.	2.5	14
155	Paediatric radiation oncology in the care of childhood cancer: A position paper by the International Paediatric Radiation Oncology Society (PROS). Radiotherapy and Oncology, 2016, 119, 357-360.	0.6	14
156	Stereotactic ablative radiation therapy prior to liver transplantation in hepatocellular carcinoma. Radiologia Medica, 2016, 121, 873-881.	7.7	14
157	A bond between rheumatic diseases and cancer in the elderly: The interleukinâ€6 pathway. International Journal of Rheumatic Diseases, 2021, 24, 1317-1320.	1.9	14
158	An international pooled analysis of SBRT outcomes to oligometastatic spine and non-spine bone metastases. Radiotherapy and Oncology, 2021, 164, 98-103.	0.6	14
159	Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial. Blood Advances, 2021, 5, 4504-4514.	5.2	14
160	Survival trends of childhood cancer diagnosed during 1970-1994 in Piedmont, Italy: A report from the Childhood Cancer Registry. Medical and Pediatric Oncology, 2001, 36, 481-488.	1.0	13
161	Absolute and relative dose measurements with Gafchromicâ,,¢ EBT film for high energy electron beams with different doses per pulse. Medical Physics, 2008, 35, 5463-5470.	3.0	13
162	Head and neck region consolidation radiotherapy and prophylactic cranial irradiation with hippocampal avoidance delivered with helical tomotherapy after induction chemotherapy for non-sinonasal neuroendocrine carcinoma of the upper airways. Radiation Oncology, 2012, 7, 21.	2.7	13

#	Article	IF	CITATIONS
163	Combined chemoradiation for head and neck region myxofibrosarcoma of the maxillary sinus. Tumori, 2013, 99, e80-e83.	1.1	13
164	Interobserver variability in clinical target volume delineation for primary mediastinal B-cell lymphoma. Practical Radiation Oncology, 2015, 5, 383-389.	2.1	13
165	Hypofractionated Whole-Breast Radiotherapy and Concomitant Boost after Breast Conservation in Elderly Patients. Tumori, 2016, 102, 196-202.	1.1	13
166	Management of acute skin toxicity with Hypericum perforatum and neem oil during platinum-based concurrent chemo-radiation in head and neck cancer patients. Medical Oncology, 2017, 34, 30.	2.5	13
167	A multinational report of technical factors on stereotactic body radiotherapy for oligometastases. Future Oncology, 2017, 13, 1081-1089.	2.4	13
168	No differences in radiological changes after 3D conformal <i>vs</i> VMAT-based stereotactic radiotherapy for early stage non-small cell lung cancer. British Journal of Radiology, 2017, 90, 20170143.	2.2	13
169	Multimodal Treatment of Advanced Mucosal Melanoma in the Era of Modern Immunotherapy. Cancers, 2020, 12, 3131.	3.7	13
170	The Impact of the COVID-19 Pandemic on Head and Neck Cancer Diagnosis in the Piedmont Region, Italy: Interrupted Time-Series Analysis. Frontiers in Public Health, 2022, 10, 809283.	2.7	13
171	Prostate-specific antigen kinetics after I125-brachytherapy for prostate adenocarcinoma. World Journal of Urology, 2013, 31, 411-415.	2.2	12
172	Salvage External Beam Radiotherapy for Recurrent Prostate Adenocarcinoma after High-Intensity Focused Ultrasound as Primary Treatment. Urologia Internationalis, 2013, 90, 288-293.	1.3	12
173	Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous non-small cell lung cancer (NSCLC). Lung Cancer, 2015, 88, 160-166.	2.0	12
174	Three-Dimensional Ultrasound-Based Image-Guided Hypofractionated Radiotherapy for Intermediate-Risk Prostate Cancer: Results of a Consecutive Case Series. Cancer Investigation, 2015, 33, 23-28.	1.3	12
175	LIMITED STAGE FOLLICULAR LYMPHOMA: THE ROLE OF RADIATION THERAPY Mediterranean Journal of Hematology and Infectious Diseases, 2016, 8, 2016041.	1.3	12
176	Post-ABVD/pre-radiotherapy ¹⁸ F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients. British Journal of Radiology, 2016, 89, 20150983.	2.2	12
177	Ablative Approaches for Pulmonary Metastases. Thoracic Surgery Clinics, 2016, 26, 19-34.	1.0	12
178	Automatic genetic planning for volumetric modulated arc therapy: A large multi-centre validation for prostate cancer. Radiotherapy and Oncology, 2020, 148, 126-132.	0.6	12
179	Sinonasal Side Effects of Chemotherapy and/or Radiation Therapy for Head and Neck Cancer: A Literature Review. Cancers, 2022, 14, 2324.	3.7	12
180	Treatment options in skeletal localizations of hairy cell leukemia: A systematic review on the role of radiation therapy. American Journal of Hematology, 2007, 82, 1017-1021.	4.1	11

#	Article	IF	CITATIONS
181	Prospective phase II trial of neoadjuvant chemo-radiotherapy with Oxaliplatin and Capecitabine in locally advanced rectal cancer (XELOXART). Medical Oncology, 2013, 30, 581.	2.5	11
182	Management of â€~In-Field' Skin Toxicity in Head and Neck Cancer Patients Treated with Combined Cetuximab and Radiotherapy. Oncology, 2013, 85, 257-261.	1.9	11
183	¹²⁵ I Brachytherapy for Localized Prostate Cancer: A Single Institution Experience. Tumori, 2013, 99, 83-87.	1.1	11
184	Leptomeningeal Metastasis from Prostate Cancer. Tumori, 2013, 99, e6-e10.	1.1	11
185	Hypofractionation with no boost after breast conservation in early-stage breast cancer patients. Medical Oncology, 2016, 33, 108.	2.5	11
186	Pathological prognostic markers in central nervous system solitary fibrous tumour/hemangiopericytoma: Evidence from a small series. PLoS ONE, 2018, 13, e0203570.	2.5	11
187	Applying radiation protection and safety in radiotherapy. Radiologia Medica, 2019, 124, 777-782.	7.7	11
188	Clinical evaluation of a transmission detector system and comparison with a homogeneous 3D phantom dosimeter. Physica Medica, 2019, 58, 159-164.	0.7	11
189	Role of radiotherapy in the management of brain metastases of NSCLC – Decision criteria in clinical routine. Radiotherapy and Oncology, 2021, 154, 269-273.	0.6	11
190	European radiation oncology after one year of COVID-19 pandemic. Clinical and Translational Radiation Oncology, 2021, 28, 141-143.	1.7	11
191	Is clinical radiosensitivity a complex genetically controlled event?. Tumori, 2006, 92, 87-91.	1.1	11
192	Induction Chemotherapy and Sequential Concomitant Chemo-radiation in Locally Advanced Head and Neck Cancers: How Induction-phase Intensity and Treatment Breaks May Impact on Clinical Outcomes. Anticancer Research, 2015, 35, 6247-54.	1.1	11
193	Peripheral blood complete remission after splenic irradiation in Mantle-Cell Lymphoma with 11q22-23 deletion and ATM inactivation. Radiation Oncology, 2006, 1, 35.	2.7	10
194	Scleromyxedema: treatment of widespread cutaneous involvement by total skin electron-beam therapy. International Journal of Dermatology, 2007, 46, 864-867.	1.0	10
195	Combination of novel systemic agents and radiotherapy for solid tumors – Part II: An AIRO (Italian) Tj ETQq1 Reviews in Oncology/Hematology, 2019, 134, 104-119.	1 0.78431 4.4	4 rgBT /Over 10
196	Running a Radiation Oncology Department at the Time of Coronavirus: An Italian Experience. Advances in Radiation Oncology, 2020, 5, 3-6.	1.2	10
197	Decreasing treatment burden in HPV-related OPSCC: A systematic review of clinical trials. Critical Reviews in Oncology/Hematology, 2021, 160, 103243.	4.4	10
198	Prognostic Characterization of Higher-Grade Meningiomas: A Histopathological Score to Predict Progression and Outcome. Journal of Neuropathology and Experimental Neurology, 2019, 78, 248-256.	1.7	10

#	Article	IF	CITATIONS
199	Stereotactic Body Radiation Therapy for Early Non-Small Cell Lung Cancer: Experience at the University of Turin. Journal of Thoracic Oncology, 2007, 2, S47.	1.1	9
200	May non-metastatic clinically localized castration-resistant prostate cancer after primary androgen ablation benefit from salvage prostate radiotherapy?. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1955-1960.	2.5	9
201	Bilateral Breast Radiation Delivered with Static Angle Tomotherapy (TomoDirect): Clinical Feasibility and Dosimetric Results of a Single Patient. Tumori, 2015, 101, e4-e8.	1.1	9
202	A national multicenter study on 1072 DCIS patients treated with breast-conserving surgery and whole breast radiotherapy (COBCG-01 study). Radiotherapy and Oncology, 2019, 131, 208-214.	0.6	9
203	Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM). Tumori, 2019, 105, 3-14.	1.1	9
204	Role of Postoperative Radiotherapy in the Management for Resected NSCLC – Decision Criteria in Clinical Routine Pre- and Post-LungART. Clinical Lung Cancer, 2021, 22, 579-586.	2.6	9
205	YKL-40 expression in anal carcinoma predicts shorter overall and disease-free survival. Histopathology, 2009, 55, 238-240.	2.9	8
206	Dose to Pelvic Bone Marrow Defined with FDG-PET Predicts for Hematologic Nadirs in Anal Cancer Patients Treated with Concurrent Chemo-radiation. Cancer Investigation, 2018, 36, 279-288.	1.3	8
207	The effects on pain and activity of daily living caused by crusted exudation in patients with head and neck cancer treated with cetuximab and radiotherapy. Supportive Care in Cancer, 2012, 20, 2141-2147.	2.2	7
208	Efficacy and Safety of Stereotactic Ablative Radiotherapy in Patients with Previous Pneumonectomy. Tumori, 2015, 101, 148-153.	1.1	7
209	What do radiation oncologists require for future advancements in lung SBRT?. Physica Medica, 2017, 44, 150-156.	0.7	7
210	Volumetric modulated arc therapy (VMAT) in the treatment of esophageal cancer patients. Medical Oncology, 2018, 35, 150.	2.5	7
211	Combination of novel systemic agents and radiotherapy for solid tumors – part I: An AIRO (Italian) Tj ETQq1 1 Reviews in Oncology/Hematology, 2019, 134, 87-103.	0.784314 4.4	rgBT /Over o 7
212	Immune Checkpoint Inhibitors in Combination with Radiotherapy as Salvage Treatment for Relapsed/Refractory Classical Hodgkin Lymphoma: A retrospective Analysis in 12 Patients. Hematology Reports, 2021, 13, 9080.	0.8	7
213	Efficacy of low-dose radiotherapy (2 Gy × 2) in the treatment of marginal zone and mucosa-associated lymphoid tissue lymphomas. British Journal of Radiology, 2021, 94, 20210012.	2.2	7
214	Changes in Patterns of Practice for Prostate Cancer Radiotherapy in Italy 1995–2003. A Survey of the Prostate Cancer Study Group of the Italian Radiation Oncology Society. Tumori, 2014, 100, 31-37.	1.1	7
215	Volumetric modulated arc therapy (VMAT) in the combined modality treatment of anal cancer patients. British Journal of Radiology, 2016, 89, 20160832.	2.2	7
216	Activity of Weekly Paclitaxel in Advanced Hormone-Refractory Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 234-238.	1.3	6

#	Article	IF	CITATIONS
217	Eyelid Localization in Mantle Cell Lymphoma: Long-Lasting Complete Remission after Surface Brachytherapy. Tumori, 2009, 95, 385-388.	1.1	6
218	Neoadjuvant chemo-radiotherapy for locally advanced esophageal cancer: A monocentric study. Tumori, 2012, 98, 451-457.	1.1	6
219	Reliability of prostate-specific antigen-marker in determining biochemical failure during the first 2 years after external beam radiation therapy and hormone therapy in patients with non-operated prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 30.e1-30.e7.	1.6	6
220	Optimal gross tumor volume definition in lung-sparing intensity modulated radiotherapy for pleural mesothelioma: an in silico study. Acta OncolA³gica, 2016, 55, 1450-1455.	1.8	6
221	Pre-operative treatments for adenocarcinoma of the lower oesophagus and gastro-oesophageal junction: a review of the current evidence from randomized trials. Medical Oncology, 2017, 34, 40.	2.5	6
222	Hypofractionated radiation therapy versus chemotherapy with temozolomide in patients affected by RPA class V and VI glioblastoma: a randomized phase II trial. Journal of Neuro-Oncology, 2019, 143, 447-455.	2.9	6
223	Two distinct prognostic groups in advanced-stage Hodgkin lymphoma revealed by the presence and site of bulky disease. Blood Advances, 2020, 4, 2064-2072.	5.2	6
224	Concurrent Chemoradiation in Anal Cancer Patients Delivered with Bone Marrow-Sparing IMRT: Final Results of a Prospective Phase II Trial. Journal of Personalized Medicine, 2021, 11, 427.	2.5	6
225	Late metastatic presentation is associated with improved survival and delayed wideâ€spread progression after ablative stereotactic body radiotherapy for oligometastasis. Cancer Medicine, 2021, 10, 6189-6198.	2.8	6
226	EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy. Blood, 2019, 134, 124-124.	1.4	6
227	The role of motion management and position verification in lymphoma radiotherapy. British Journal of Radiology, 2021, 94, 20210618.	2.2	6
228	Development of a Prognostic Model for Overall Survival in Patients With Extracranial Oligometastatic Disease Treated With Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2022, 114, 892-901.	0.8	6
229	Polyostotic Sclerosing Histiocytosis (Erdheim-Chester Disease) Treated with Combined Vertebroplasty and Radiation Therapy. Tumori, 2010, 96, 633-636.	1.1	5
230	Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approach. PLoS ONE, 2019, 14, e0224027.	2.5	5
231	Radiation-Induced Lymphopenia Beyond the COVID-19 Pandemic. Frontiers in Oncology, 2020, 10, 617302.	2.8	5
232	COVID-19 safe and fully operational radiotherapy: An AIRO survey depicting the Italian landscape at the dawn of phase 2. Radiotherapy and Oncology, 2021, 155, 120-122.	0.6	5
233	An integrated approach to cardioprotection in lymphomas. Lancet Haematology,the, 2022, 9, e445-e454.	4.6	5
234	Predictors of Bone Metastases at 68Ga-PSMA-11 PET/CT in Hormone-Sensitive Prostate Cancer (HSPC) Patients with Early Biochemical Recurrence or Persistence. Diagnostics, 2022, 12, 1309.	2.6	5

#	Article	IF	CITATIONS
235	Palliative Radiotherapy for Painful Bone Metastases from Solid Tumors Delivered with Static Ports of Tomotherapy (TomoDirect): Feasibility and Clinical Results. Cancer Investigation, 2014, 32, 458-463.	1.3	4
236	Stereotactic ablative radiotherapy in the treatment of hepatocellular carcinoma >3Âcm. Medical Oncology, 2016, 33, 104.	2.5	4
237	Role of consolidative stereotactic ablative radiotherapy in patients with oligometastatic non-small cell lung cancer. Journal of Thoracic Disease, 2017, 9, 2235-2237.	1.4	4
238	What is the role of reirradiation in the management of locoregionally relapsed non small-cell lung cancer?. Lung Cancer, 2020, 146, 263-275.	2.0	4
239	Adoption of Expansion Margins to Reduce the Dose Received by the Coronary Arteries and the Risk of Cardiovascular Events in Lymphoma Patients. Practical Radiation Oncology, 2021, 11, 66-73.	2.1	4
240	Safety of lung stereotactic ablative radiotherapy for the functioning of cardiac implantable electronic devices. Radiotherapy and Oncology, 2021, 156, 193-198.	0.6	4
241	How Has Prostate Cancer Radiotherapy Changed in Italy between 2004 and 2011? An Analysis of the National Patterns-Of-Practice (POP) Database by the Uro-Oncology Study Group of the Italian Society of Radiotherapy and Clinical Oncology (AIRO). Cancers, 2021, 13, 2702.	3.7	4
242	Harnessing benefit of highly conformal RT techniques for lymphoma patients. British Journal of Radiology, 2021, 94, 20210469.	2.2	4
243	Automated Heuristic Optimization of Prostate VMAT Treatment Planning. International Journal of Medical Physics, Clinical Engineering and Radiation Oncology, 2018, 07, 414-425.	0.1	4
244	Volumetric burden of metastatic lesions drives outcomes in patients with extracranial oligometastatic disease. Cancer Medicine, 2021, 10, 8091-8099.	2.8	4
245	Treatment of metastatic melanoma: a multidisciplinary approach. Italian Journal of Dermatology and Venereology, 2017, 152, 241-261.	0.2	4
246	Image-guided Intensity-modulated Radiotherapy for Prostate Cancer Employing Hypofractionation and Simultaneous Integrated Boost: Results of a Consecutive Case Series with Focus on Erectile Function. Anticancer Research, 2015, 35, 4177-82.	1.1	4
247	Phase II study of intensive chemotherapy with carboplatin, ifosfamide and etoposide plus recombinant human granulocyte colony-stimulating factor and sequential radiotherapy in locally advanced, unresectable non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology, 1996, 38, 561-565.	2.3	3
248	Emerging treatment options in the management of non-small cell lung cancer. Lung Cancer: Targets and Therapy, 2011, 2, 11.	2.7	3
249	Radical radiotherapy in high-risk prostate cancer patients with high or ultra-high initial PSA levels: a single institution analysis. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1141-1147.	2.5	3
250	THE EVOLVING ROLE OF RADIOTHERAPY IN EARLY STAGE HODGKIN'S LYMPHOMA. Mediterranean Journal of Hematology and Infectious Diseases, 2014, 6, e2014035.	1.3	3
251	Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC. Lung Cancer, 2016, 100, 30-37.	2.0	3
252	National societies' needs as assessed by the ESTRO National Societies Committee survey: A European perspective. Radiotherapy and Oncology, 2020, 151, 176-181.	0.6	3

UMBERTO RICARDI

#	Article	IF	CITATIONS
253	A study to investigate the influence of cardiac motion on the robustness of pencil beam scanning proton plans in oesophageal cancer. Physics and Imaging in Radiation Oncology, 2020, 16, 50-53.	2.9	3
254	Role of Radiotherapy in Post-transplant Lymphoproliferative Disorders: Three Case Reports and Review of the Literature. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e309-e316.	0.4	3
255	Innovative technologies in thoracic radiation therapy for lung cancer. Translational Lung Cancer Research, 2012, 1, 263-8.	2.8	3
256	A Case of Bone Involvement in Hairy Cell Leukemia Successfully Treated with Radiation Therapy. Tumori, 2006, 92, 366-369.	1.1	2
257	Minimizing a Tricky Situation in Breast Irradiation with Helical Tomotherapy. Tumori, 2014, 100, e35-e40.	1.1	2
258	In Reply to Adams and Kwee. International Journal of Radiation Oncology Biology Physics, 2015, 93, 725-726.	0.8	2
259	Alternative options for elderly patients with limited stage diffuse large B-cell lymphoma: R-chemotherapy vs. R-chemotherapy plus radiotherapy. Leukemia and Lymphoma, 2016, 57, 2677-2680.	1.3	2
260	The importance of IL-6 blockade beyond the COVID-19 pandemic: Consideration for cancer care. Radiotherapy and Oncology, 2020, 151, 24-25.	0.6	2
261	Radiation therapy for oligometastatic oropharyngeal cancer. BJR case Reports, 2020, 6, 20190021.	0.2	2
262	An external validation of the Candiolo nomogram in a cohort of prostate cancer patients treated by externalâ€beam radiotherapy. Radiation Oncology, 2021, 16, 85.	2.7	2
263	Do hypofraction and large breast size reciprocally fit in breast cancer radiotherapy?. Annals of Translational Medicine, 2019, 7, S146-S146.	1.7	2
264	Primary tumor size as a prognosticator in anal cancer patients. Annals of Translational Medicine, 2019, 7, 157-157.	1.7	2
265	Risk Stratification System and Pattern of Relapse in Patients Treated with Adjuvant Radiotherapy after Radical Prostatectomy. Tumori, 2016, 102, 323-329.	1.1	1
266	Cardiometabolic Risk, Part 1: Chemotherapy and Radiotherapy – Old Foes Still Threatening Cancer Survivors?. Frontiers of Hormone Research, 2021, 54, 115-129.	1.0	1
267	Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi. Annals of Hematology, 2021, 100, 2547-2556.	1.8	1
268	"Miro―Study, a FIL multicenter phase II trial combining local radiotherapy and MRD-driven immunotherapy in early-stage follicular lymphoma Journal of Clinical Oncology, 2020, 38, e20073-e20073.	1.6	1
269	The waiting time for prostate cancer treatment in Italy: analysis from the Pros-IT CNR study. Minerva Urology and Nephrology, 2020, , .	2.5	1
270	Adjuvant malignant mesothelioma radiotherapy: How many difficulties! In regard to: Allen et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma (Int J Radiat) Tj ETQq0 0 0 pleurectomy/decortication for malignant pleural mesothelioma (Int J Radiat Oncol Biol Phys) Tj ETQq0 0 0 rgBT /	0.8	0

#	ARTICLE	IF	CITATIONS
271	Radiotherapy in Pleural Malignant Mesothelioma: Why not! in Regard to Scorsetti et al. (Int J Radiat) Tj ETQq1 1 International Journal of Radiation Oncology Biology Physics, 2011, 79, 1279.	0.784314 0.8	rgBT /Overlo O
272	Radiation therapy in locally advanced non-small-cell lung cancer: an overview of dose/fractionation strategies to improve outcomes. Lung Cancer Management, 2012, 1, 227-235.	1.5	0
273	Adjuvant radiotherapy for malignant pleural mesothelioma: Challenges and pitfalls. Radiotherapy and Oncology, 2012, 105, 271.	0.6	0
274	FDG-PET and radiotherapy in lymphoma. Clinical and Translational Imaging, 2015, 3, 321-330.	2.1	0
275	Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup. ESMO Open, 2017, 2, e000141.	4.5	0
276	Stage I Nonsmall Cell Lung Cancer and Oligometastatic Disease. , 2018, , 342-354.e4.		0
277	How radical prostatectomy procedures have changed over the last 10Âyears in Italy: a comparative analysis based on more than 1500 patients participating in the MIRROR-SIU/LUNA and the Pros-IT CNR study. World Journal of Urology, 2021, 39, 1445-1452.	2.2	0
278	Radiotherapy treatment strategies for squamous cell carcinoma of the cervical oesophagus: moving toward better outcomes. Annals of Translational Medicine, 2017, 5, 426-426.	1.7	0
279	Simulation modeling for clinical trials evaluating radiotherapy omission in low-risk early breast cancer. Annals of Translational Medicine, 2018, 6, S43-S43.	1.7	0
280	GCT-48. OUTCOME OF CNS MALIGNANT NON-GERMINOMATOUS GERM CELL TUMORS (GCT) WITH AFP > 1000 ng/ml AT DIAGNOSIS TREATED ACCORDING TO SIOP CNS GCT 96. Neuro-Oncology, 2020, 22, iii337-iii338.	1.2	0
281	Role of Radiosurgery and Stereotactic Ablative Radiotherapy for Oligometastatic Non-Oncogene Addicted NSCLC. Cancers, 2022, 14, 1465.	3.7	0
282	Development of a prognostic model of overall survival in oropharyngeal cancer from real-world data: PRO.M.E.THE.O Acta Otorhinolaryngologica Italica, 2022, , 1-10.	1.5	0
283	Title is missing!. , 2019, 14, e0224027.		0
284	Title is missing!. , 2019, 14, e0224027.		0
285	Title is missing!. , 2019, 14, e0224027.		0
286	Title is missing!. , 2019, 14, e0224027.		0
287	Title is missing!. , 2019, 14, e0224027.		0
288	Title is missing!. , 2019, 14, e0224027.		0